Latigo Biotherapeutics, Inc. (LTGO) Debt Components
- 2026-06-30: Convertible Notes Payable, CurrentUSD $29.90M; Convertible Notes PayableUSD $35.00M; Long-term Debt, GrossUSD $35.00M; Debt Instrument, Face AmountUSD $35.00M.
- 2025-12-31: Convertible Notes Payable, CurrentUSD $0.00; Convertible Notes PayableUSD (m); Long-term Debt, GrossUSD (m); Debt Instrument, Face AmountUSD (m).
Latigo Biotherapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Convertible Notes Payable USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Unamortized Discount, Current USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29.90M | $35.00M | $35.00M | $35.00M | 5.00% | $4.96M |
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |